Level D· Scientific groundwork from lab and animal studiesLaboratory StudyPubMedOpen access

Effects of optogenetic stimulation on neural gene expression in human bone marrow and adipose-derived mesenchymal stem cells.

Fereidounian MA., Bourbour S., Shirkavand A., Neghab HK., Pirouz MS., Mohajerani E.

Laboratory Study on Face & Skin, published in BMC Biotechnol (2025) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Laboratory Study
Journal
BMC Biotechnol (2025)
Country
England
Reported sample size
—
Source database
PubMed
PMID
41361873
PMCID
PMC12797768
DOI
10.1186/s12896-025-01083-0

Abstract (original English)

BACKGROUND: Bone Marrow-derived Mesenchymal Stem Cells (BM-MSCs) and adipose tissue are widely applied in tissue engineering. Optogenetics enables millisecond-scale spatial and temporal control of particular cell populations. In this technology, genetically-modified cells, that express light-sensitive opsins, are stimulated or inhibited by light. Since an increase in intracellular cation flow is one of the causal factors of stem cell differentiation, the purpose of this study was to investigate the alterations in the expression levels of crucial neural biomarkers in BM-MSCs and Adipose-MSCs (A-MSCs) in terms of channelrhodopsin-2 (ChR2) expression and non-expression, low-power blue light radiation, or a combination of both treatments. METHODS: A plasmid vector encoding the ChR2 (H134R) opsin protein gene, which belongs to the group of opsins activated by blue light, fused with the EYFP fluorescent protein gene, was employed in this study. After adding the plasmid vector to both BM-MSCs and A-MSCs, the surface expression of the EYFP fluorescent protein underneath a fluorescent microscope was examined. The conditioned cells were exposed to low-power blue light (470 nm wavelength, variable pulse width, 1 Hz frequency, and 1 mW power for 1-hour irradiation). RESULTS: The results indicated that integrating the plasmid vector into BM-MSCs and A-MSCs, along with expressing ChR2 and ap

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
Mesenchymal Stem CellsHumansOptogeneticsBone Marrow CellsAdipose TissueCell DifferentiationBlue LightChannelrhodopsinsCells, CulturedNeurons

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research